Progression-free survival remained improved versus docetaxel alone during extended follow-up.
Rates of hypophosphatemia were higher with ferric carboxymaltose than with ferric derisomaltose.
Highlights of the latest gastrointestinal cancer trials
A new guideline standardizes best diagnostic practices.
Older patients represent a large majority of newly diagnosed cases and have high risk for early death.
Early mortality was elevated in men with preexisting cardiovascular disease after receiving abiraterone acetate or enzalutamide therapy.
VTE recurrence increased with the number of metabolic syndrome components.
Risks for CRC incidence and death are higher in UC patients than in population-based controls but may be on the decline.
Cardiotoxicity during treatment may be associated with long-term impairment of cardiopulmonary function.
A randomized trial suggests a benefit, but there are important caveats.
Overall survival trended longer with the addition of palbociclib to endocrine therapy in patients with ER-positive/HER2-negative metastatic disease.
Adding atezolizumab to nab-paclitaxel prolonged progression-free survival in patients with metastatic triple-negative breast cancer.
Progression-free survival was prolonged with front-line brigatinib versus crizotinib.
Adding atezolizumab to chemotherapy significantly improved overall and progression-free survival.
Adding the PD-1 inhibitor pembrolizumab to carboplatin-taxane chemotherapy significantly improved response and survival.
Two-year overall survival was significantly improved with durvalumab versus placebo.
Long-term follow-up data confirm that axillary dissection is unnecessary in patients with minimal tumor burden in the sentinel nodes.
Progression-free survival was significantly longer with olaparib than with placebo.
Ipilimumab plus nivolumab proved safe and efficacious in a phase II trial.
Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.